토글닫기
팝업닫기

Refusal of Unauthorized Collection of E-mail Addresses

We do not allow the unauthorized collection of e-mail addresses listed on our website. Persons engaging in unauthorized collection with e-mail address collection programs or other technical devices will be subject to criminal prosecution in accordance with the Act on Information & Communications Network Utilization and Information Protection.

Contact Us

form mail list
Name *
Tel * - -
E-mail * @
Subject *
Contents
File1
File2
Spam Check* 자동등록방지번호
* 왼쪽의 자동등록방지 코드를 입력하세요.

Consent to Collect and Use Personal Information

I agree to the terms and conditions.

Platform Technology

RNAi platform development

Lead compound discovery

Pulmonology / Neurology

Pharmacological research on OliX RNAi compounds for respiratory and neurological diseases

Ophthalmology

Pharmacological research on OliX RNAi compounds for ocular diseases

Animal Research

Testing efficacy of oligonucleotide therapeutics using animal models

Analytics

Develop analytical methods for therapeutic candidates to determine purity and stability in support of nonclinical and clinical studies

PK/TK

Develop bioanalytical methods to quantitate therapeutic candidates in biological matrices for pharmacokinetic and toxicokinetic (PK/TK) studies

CMC

Manage manufacturing, analytics and quality of therapeutic candidates

Toxicology

Conduct safety evaluation and toxicokinetic assessment of therapeutic candidates through nonclinical studies

Clinical

Establish clinical development plans for therapeutic candidates and conduct clinical studies

Management

Business Management

Purchasing

General Affairs

Facility Management

Contingency Planning

Planning

Budget/Performance Management

Mid to Long-term Business Goals/Strategy Planning

Accounting & Finance

Make official announcements about business contents, financial condition, business performance etc.

Stabilize Internal Accounting Control System

IT

IT Infrastructure Management

IT Helpdesk

Human Resources

HR Policy/System Establishment, Organization/Job Design

Recruitment/HR Management

Performance Management, Employee Welfare

HR Development

Legal Affairs

Prevent, respond, handle legal disputes

Provide risk management and compliance support

Develop IP strategies for core technologies

Quality Assurance(QA)

Verify pharmaceutical R&D processes and results

Ensure product to meet the established quality standards

Business Development

Develop/Maintain Client Relationships

Execute Licensing Agreements

New Business/Strategy Planning

Communications

Provide investment information in a timely manner to increase company value

Promote management activities and establish internal/external communication strategies

Create positive corporate culture through various in-house activities and employee education

  • Home
  • PR

PR

News

News

게시물 목록
No. Title Date View
56
Nature Biopharma Dealmakers

Nature Biopharma Dealmakers

  • 2023-12-01
  • 조회수 : 46
 2023-12-01 46
55
OliX Announces Positive Safety Data and Preliminary Efficacy Effects in a Phase 1 Trial of OLX10212

OliX Announces Positive Safety Data and Preliminary Efficacy Effects in a Phase 1 Trial of OLX10212

  • 2023-11-30
  • 조회수 : 114
 2023-11-30 114
54
OliX Administers First Patient in Phase 1 Clinical Study of RNAi Therapeutic OLX72021 for Androgenic

OliX Administers First Patient in Phase 1 Clinical Study of RNAi Therapeutic OLX72021 for Androgenic

  • 2023-06-15
  • 조회수 : 817
 2023-06-15 817
53
OliX Presents Preclinical Data Showing Synergistic Weight Loss from anti-NASH siRNA and Semaglutide

OliX Presents Preclinical Data Showing Synergistic Weight Loss from anti-NASH siRNA and Semaglutide

  • 2023-06-02
  • 조회수 : 677
 2023-06-02 677
52
OliX Inks MOU with DynamiCure Biotechnology to Develop ADC Immunotherapy Using RNA

OliX Inks MOU with DynamiCure Biotechnology to Develop ADC Immunotherapy Using RNA

  • 2023-06-02
  • 조회수 : 620
 2023-06-02 620
51
OliX Announces Positive Results from a Phase 2a Trial of OLX10010 for Hypertrophic Scar Treatment

OliX Announces Positive Results from a Phase 2a Trial of OLX10010 for Hypertrophic Scar Treatment

  • 2023-05-09
  • 조회수 : 591
 2023-05-09 591
50
OliX Doses First Patient in Clinical Trial for RNAi Therapeutic OLX10212 for Dry and Wet AMD

OliX Doses First Patient in Clinical Trial for RNAi Therapeutic OLX10212 for Dry and Wet AMD

  • 2023-03-28
  • 조회수 : 1069
 2023-03-28 1069
49
OliX Receives Regulatory Approval to Commence Phase 1 Clinical Trial of Treatment of Androgenic Alop

OliX Receives Regulatory Approval to Commence Phase 1 Clinical Trial of Treatment of Androgenic Alop

  • 2023-03-27
  • 조회수 : 1080
 2023-03-27 1080
48
OliX Publishes Preclinical Research Demonstrating OLX104C’s Potential as an Effective Treatment for

OliX Publishes Preclinical Research Demonstrating OLX104C’s Potential as an Effective Treatment for

  • 2022-11-28
  • 조회수 : 1569
 2022-11-28 1569
47
OliX Announces Positive Preclinical Data in NASH Non-human Primate Models

OliX Announces Positive Preclinical Data in NASH Non-human Primate Models

  • 2022-11-10
  • 조회수 : 958
 2022-11-10 958
46
OliX Receives IND Approval from FDA to Develop RNAi Therapeutic OLX10212 for AMD

OliX Receives IND Approval from FDA to Develop RNAi Therapeutic OLX10212 for AMD

  • 2022-08-08
  • 조회수 : 1556
 2022-08-08 1556
45
OliX Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212

OliX Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212

  • 2022-07-05
  • 조회수 : 1502
 2022-07-05 1502
44
OliX Subsidiary mCureX Announces mRNA Technology Collaboration with ToolGen for Rare Eye Disease

OliX Subsidiary mCureX Announces mRNA Technology Collaboration with ToolGen for Rare Eye Disease

  • 2022-07-05
  • 조회수 : 1335
 2022-07-05 1335
43
OliX to Conduct Business Meetings with Potential Partners at 2022 BIO International Convention

OliX to Conduct Business Meetings with Potential Partners at 2022 BIO International Convention

  • 2022-06-13
  • 조회수 : 1444
 2022-06-13 1444
42
OliX Announces Completion of Enrollment in Phase 2 Clinical Trial of OLX101A in Patients with Hypert

OliX Announces Completion of Enrollment in Phase 2 Clinical Trial of OLX101A in Patients with Hypert

  • 2022-06-07
  • 조회수 : 1745
 2022-06-07 1745
41
OliX Announces Completion of USD 45 Million Capital Raise for R&D and Financial Structure Improvemen

OliX Announces Completion of USD 45 Million Capital Raise for R&D and Financial Structure Improvemen

  • 2022-05-27
  • 조회수 : 2442
 2022-05-27 2442
40
OliX Identifies Effective Inhibition of Target Gene expression and Delivery of Candidate to Brain

OliX Identifies Effective Inhibition of Target Gene expression and Delivery of Candidate to Brain

  • 2022-05-27
  • 조회수 : 1386
 2022-05-27 1386
39
OliX Identifies Inhibition of Target Gene expression in Nonhuman Primate Models for NASH Candidate

OliX Identifies Inhibition of Target Gene expression in Nonhuman Primate Models for NASH Candidate

  • 2022-04-12
  • 조회수 : 1968
 2022-04-12 1968
38
OliX Pharmaceuticals to Participate in BIO-Europe Spring®

OliX Pharmaceuticals to Participate in BIO-Europe Spring®

  • 2022-03-24
  • 조회수 : 1662
 2022-03-24 1662
37
OliX Pharmaceuticals Presents Potential Utility of GalNAc-asiRNA Platform at OPT Congress

OliX Pharmaceuticals Presents Potential Utility of GalNAc-asiRNA Platform at OPT Congress

  • 2022-03-22
  • 조회수 : 2070
 2022-03-22 2070